IPIX has had 5 PRs specific to the B-IBD Oral Phase 1 and an additional 4 shareholder alerts since 1/9/20 specific to this study. From the 1/9/20 shareholder alert announcing the site initiation to the 2/13/20 PR announcing positive Top Line results, the entire Phase 1 took a little over a month to complete. IMO this was an incredibly fast and efficient study. I am assuming that doing the study overseas and having an EU subsidiary greatly helped in getting this study completed expeditiously. Note that there was only 3 weeks between the Top Line Result PR on 2/13/20 and The Plan for Phase 2 and interviewing a CRO PR on 3/5/20. As I have stated before I believe Leo has funding identified for the B-IBD Oral Phase 2 or he would not have issued the 3/5/20 PR. Getting B-IBD Oral to market to address a $48B opportunity represents an exciting and wealth building initiative.
There also was the B-OM PR on 1/29/20 entitled Further Engagement of Locust Walk to Lead B-OM negotiation. We could see a B-OM partnership deal announced at any time. Getting B-OM to market addresses a critical need and would further give IPIX credibility and visibility in the overall cancer market as IPIX advances the Kevetrin science.
We have 3 separate initiatives with B-OM, B-IBD Oral and COVID-19 that could each have major announcements at any time that could have a major impact on shareholder value.
There also was the B-OM PR on 1/29/20 entitled Further Engagement of Locust Walk to Lead B-OM negotiation. We could see a B-OM partnership deal announced at any time. Getting B-OM to market addresses a critical need and would further give IPIX credibility and visibility in the overall cancer market as IPIX advances the Kevetrin science.
We have 3 separate initiatives with B-OM, B-IBD Oral and COVID-19 that could each have major announcements at any time that could have a major impact on shareholder value.
9
